ANGPT2 and ovarian carcinoma: Secondly, a bispecific Ang2/VEGF-A-targeting mAb, Vanucizumab, underwent a Phase I trial in ovarian cancer patients and demonstrated potential clinical activity, with 20% of patients displaying an OR (Figure 3) [94].